MIAMI--(BUSINESS WIRE)--Jan. 30, 2006--DOR BioPharma, Inc. (AMEX:DOR) (“DOR”, or the “Company”) today announced results of a Phase I clinical trial of RiVax(TM), a recombinant vaccine against ricin toxin, that has been completed by investigators at the University of Texas Southwestern Medical Center (UT Southwestern) led by Dr. Ellen Vitetta, director of the Cancer Immunobiology Center at UT Southwestern. The results of the Phase I safety and immunogenicity dose-escalation study indicate that the vaccine is well tolerated and induces antibodies in humans that neutralize ricin toxin. The outcome of the study will be published this week in the online edition of the Proceedings of the National Academy of Sciences.
